SCN1A and Dravet syndrome: This was associated with a concurrent reduction in seizure frequency and fatality following ASO-TANGO treatment in a mouse model of Dravet syndrome.7 A similar method used an oligonucleotide-derived compound (AntagoNAT) to knock-down antisense noncoding RNA that suppresses Scn1a expression.